JP Morgan Chase
TVRD

JP Morgan Chase’s Tvardi Therapeutics TVRD Stock Holding History

JP Morgan Chase’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,617
Closed -$9.08M – 6666
2021
Q1 		$9.08M Buy
+11,617
New +$7.95M ﹤0.01% 2452
2019
Q3 		– Sell
-2,931
Closed -$2.23M – 6002
2019
Q2 		$2.23M Buy
+2,931
New +$2.06M ﹤0.01% 3307
2017
Q3 		– Sell
-2,500
Closed -$1.39M – 5224
2017
Q2 		$1.39M Buy
+2,500
New +$1.59M ﹤0.01% 3262

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

JP Morgan Chase's TVRD Position: Q2 2026 in Review

JP Morgan Chase reduced its Tvardi Therapeutics (TVRD) stake by 95% in Q2 2026, selling an estimated $7.65K and leaving 126 shares worth $240. The position accounts for ﹤0.01% of the portfolio, ranked #7482.

JP Morgan Chase first reported a position in TVRD in Q1 2014 and has held it in 50 quarters since. The position peaked at $6.78M in Q1 2014. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • JP Morgan Chase held 126 shares of Tvardi Therapeutics worth $240 as of Q2 2026.
  • JP Morgan Chase sold 2,439 Tvardi Therapeutics shares in Q2 2026, an estimated $7.65K.
  • Tvardi Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7482 holding.
  • JP Morgan Chase first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 50 quarters since.
  • JP Morgan Chase's Tvardi Therapeutics position peaked at $6.78M in Q1 2014.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.